Breathing Interventions and CO2 Optimization
1 Carbon Dioxide as Vasodilator and Oxygen Facilitator
CO2 serves two critical physiological roles often overlooked in ME/CFS: it is a potent vasodilator (opening blood vessels to increase tissue perfusion) and it facilitates oxygen release from hemoglobin via the Bohr Effect. Low CO2 levels therefore impair both blood delivery and cellular oxygenation simultaneously, compounding the hypoperfusion discussed in Cardiovascular Dysfunction.
Falsifiability: weakly — Falsified if ME/CFS patients with normal muscular O2 extraction (by invasive CPET) still show low ETCO2, or if respiratory rate is elevated rather than respiratory depth
ME/CFS patients exhibit low end-tidal CO2 (ETCO2), but this appears to result from impaired cellular respiration rather than primary hyperventilation. Wood et al. (2022) found that 74% of Long~COVID patients had ETCO2 below 35~mmHg despite normal respiratory rate Natelson identified “hyperpnea” (deeper breathing) rather than tachypnea (faster breathing) in ME/CFS—a compensatory response to poor muscular O2 extraction. Rossman and Van der Togt (2023) proposed that intramuscular acidosis from anaerobic metabolism drives respiratory compensation
Orthostatic stress dramatically worsens CO2 loss. Visser et al. (2023) measured ETCO2 during tilt-table testing
- ME/CFS without POTS: 37 → 30~mmHg (7~mmHg drop)
- ME/CFS with POTS: 36 → 26~mmHg (10~mmHg drop)
- Healthy controls: 37 → 36~mmHg (1~mmHg drop)
- 53% of ME/CFS patients fell below the 30~mmHg clinical reference range while standing
Certainty: 0.50—the data are consistent across studies, but direct demonstration that low CO2 is secondary to impaired muscular respiration (rather than an independent central respiratory drive abnormality) requires simultaneous measurement of tissue O2 extraction and ETCO2.
Even if low CO2 in ME/CFS is confirmed as a consequence of impaired muscular respiration, it does not automatically follow that breathing techniques to raise CO2 will alleviate symptoms. No clinical trial of adapted Buteyko breathing in ME/CFS has been published. The practitioner recommendations in this section (Courtney, McKeown) derive from clinical experience reported in Ussher (2025), not from peer-reviewed research.
2 Buteyko Breathing Method
The Buteyko Method, developed by Ukrainian physician Konstantin Buteyko (1923–2003), aims to normalize breathing patterns by reducing breathing depth to build CO2 levels. The core measurement is the “Control Pause”: the time one can comfortably hold the nose after a normal exhalation before the first distinct urge to breathe. A longer Control Pause reflects higher baseline CO2 and better CO2 tolerance.
3 ME/CFS Adaptation
Some Buteyko practitioners claim chronic hyperventilation causes ME/CFS. The evidence discussed above suggests the reverse: ME/CFS causes low CO2. Standard Buteyko targets (40+ second Control Pause, 3–4 hours daily practice) are unrealistic and potentially harmful for ME/CFS patients. The adapted approach below uses gentle techniques with realistic goals.
Rosalba Courtney (Australian PhD specializing in dysfunctional breathing in ME/CFS) advises that ME/CFS hyperventilation is driven by mitochondrial and pulmonary limitations, requiring a gentle rather than aggressive approach:
- Realistic targets: Starting Control Pause typically 5–15 seconds; achievable target 20 seconds (a meaningful physiological improvement); 40+ seconds unrealistic while ill
- Daily habits: Nasal breathing during the day (mouth breathing loses CO2); mouth taping at night with hypoallergenic tape; walking at a pace that does not deepen breathing
- Breath reduction exercises: Reduce breathing depth by 10–25% while sitting; start with 5 breaths, build to 5–20 minute sessions. The resulting mild air hunger is the training stimulus
- Steps practice: Walk while holding the nose (start with 10 steps, progress gradually). This teaches muscles to extract oxygen with less available air and may modify the anaerobic threshold—McKeown notes it mimics high-altitude training effects and may increase red blood cell mass
- Integration with pacing: Walking pace should be set by breathing, not perceived effort. If breathing deepens, the pace is too fast
4 Buteyko-Style Breathing for Cerebral Blood Flow Stabilization
Certainty: 0.50. ME/CFS patients are chronically hypocapnic during orthostasis, with ETCO2 of 33.9~mmHg vs 42.8~mmHg in healthy controls (Medow and Stewart 2024). Chronic hypocapnia (even without tachypnoea) reduces cerebral blood flow velocity via CO2-mediated vasoconstriction — every 1~mmHg reduction in ETCO2 below 40~mmHg reduces CBFv by approximately 2–4% (Badhwar et al. 2025). Buteyko-style reduced-breathing techniques (gentle breath reduction, nasal breathing, Control Pause target 20~s) could raise ETCO2 toward 40~Torr, improving cerebral oxygenation and reducing orthostatic cognitive symptoms.
Mechanistic rationale. The physiological basis is distinct from the conventional Buteyko rationale for asthma or anxiety. In ME/CFS, low ETCO2 is a consequence of impaired cellular respiration (compensatory hyperpnoea driven by poor O2 extraction), not primary hyperventilation. However, even if low CO2 is secondary, the resulting cerebral vasoconstriction creates an independent pathological contribution to brain hypoperfusion that may be therapeutically modifiable. The CO2-CBFv relationship is among the most robust in cerebrovascular physiology — raising ETCO2 from 34 to 40~mmHg should produce a ~12–24% increase in CBFv, which is clinically meaningful in a condition where orthostatic CBFv declines of ~30% are documented.
Safety. The adapted (gentle) Buteyko approach is inherently low-risk: mild air hunger during breath reduction does not trigger Valsalva or syncope. Patients with panic disorder or severe hyperventilation syndrome may require professional supervision. Must not be combined with breath-holds >10~s in POTS patients (Valsalva risk).
Testable predictions. + 4 weeks of adapted Buteyko (15~min daily breath reduction, nasal breathing, Control Pause tracking) increases ETCO2 from baseline ≤34 to ≥38~Torr + CBFv (transcranial Doppler MCA) increases ≥8% at matched workload + N-back performance (working memory) improves ≥1 SD at 4 weeks, correlating with CBFv change + The intervention is tolerated without PEM induction in ≥ 80% of mild-to-moderate ME/CFS patients
Limitations. No Buteyko trial has been performed in ME/CFS — all predictions are extrapolated from healthy physiology and one adapted-CO2-training study in Long COVID (pending publication). Individual baseline ETCO2 may determine response; patients with normal ETCO2 (>38) cannot benefit. The protocol may be less effective in severe ME/CFS where breathing drive is dominated by metabolic acidosis.
5 Structured Reconditioning: The Klimas Program
Prof. Nancy Klimas observed a clinically suggestive pattern: a patient who crashed after a continuous 12-minute walk did not crash when the same total walking time was divided into three 4-minute walks separated by 4-minute supine rests. This observation led to a structured reconditioning protocol distinct from graded exercise therapy (GET).
Physiological rationale: Supine rest between activity bouts maximizes blood return to the peripheries and muscles, temporarily ameliorating the global hypoperfusion that drives exercise intolerance (see Cardiovascular Dysfunction). The body can recover from brief exertion bursts in ways it cannot from sustained continuous effort.
Protocol structure (example progression over 6 months):
- Weeks 1–2: 3 \(\\times\) 2-minute walks daily, 2-minute supine rest after each
- Weekly progression: Add 1–2 minutes to one session; insert additional rest breaks within longer sessions
- By month 6: Morning and afternoon sessions of 8+7~min walking with 8+7~min supine rest between bouts = 30–45~min total walking per day without continuous effort
Key distinctions from GET:
- No prescribed trajectory: increases only when patient feels ready
- Rests are physiologically motivated (vascular reperfusion), not psychological
- Does not assume deconditioning is the primary problem
- Immediate rollback at any sign of PEM
- Goal is improved quality of life within illness, not “cure through exercise”
Very slow walking: Walking pace should match actual O2 extraction capacity. Breathing should remain identical before and after climbing stairs—if it deepens, the pace is too fast. Stairs and inclines require dramatic pace reduction; resting 5 seconds per step if needed.
This protocol is based on clinical observation (reported by Ussher 2025, attributed to Prof. Nancy Klimas). No published protocol paper, controlled trial, or peer-reviewed outcome data exist for this specific approach. The week-by-week progression parameters are clinical heuristics, not empirically calibrated values. The physiological rationale (supine rest for blood redistribution) is consistent with established cardiovascular physiology but has not been tested as a structured intervention in ME/CFS.
6 Compression Stockings for Orthostatic Support
Visser, Van Campen, and Rowe (2022) conducted a randomized crossover trial in 16 ME/CFS patients using knee-high 20–30~mmHg medical-grade compression stockings during tilt-table testing
- Without stockings: Cerebral blood flow reduced approximately 30% when upright
- With stockings: Cerebral blood flow reduced approximately 14% when upright
- The 16-percentage-point improvement is clinically significant, though still above the healthy control norm (~5%)
Hip-high stockings would likely show greater benefit but have not been studied. Stockings are low-cost, immediately actionable, and generally well-tolerated (contraindicated in peripheral arterial disease; some patients report heat intolerance or skin irritation). They are particularly helpful during upright activities such as shopping and social events.
7 Cerebral Perfusion Optimization as Metabolic Reserve Intervention
In the Architecture C framework (Architectural Uncertainty: Architecture A Cannot Be Ruled Out), hEDS/POTS reduces metabolic reserve via cerebral hypoperfusion — an energy delivery deficit rather than a production deficit. Interventions that improve cerebral blood flow directly increase R_headroom. These interventions are standard POTS management but are rarely framed as metabolic reserve interventions — in Architecture C, they do not just treat orthostatic symptoms but directly increase the energy available for cognitive work.
- Head-of-bed elevation (10–15 degrees). Improves cerebral venous drainage during sleep, enhancing glymphatic clearance and reducing morning brain fog.
- Graduated compression (abdominal binder + thigh-high stockings, 30–40 mmHg). Reduces venous pooling, improves venous return and cardiac output, increases cerebral blood flow. Abdominal binder particularly relevant for reclined/bedbound patients.
- Fluid and salt loading (2–3 L fluid + 5–10 g NaCl daily). Expands plasma volume. Contraindicated in hypertension. Monitor for edema. Also use caution in MCAS (GI intolerance, mast cell instability with fluid shifts) and renal impairment. Patients already on fludrocortisone or midodrine should coordinate salt loading with their prescriber — the combination risks volume overload and supine hypertension.
- Postural optimization for cognitive work. Reclined desk position (30–45 degree recline) for all cognitive tasks. Removes the orthostatic component of cerebral hypoperfusion during the activity most likely to cause cognitive PEM.
- Counterpressure manoeuvres before and during cognitive effort. Not just for presyncope — proactive use during any sustained cognitive work to maintain cerebral perfusion.
Standard POTS management interventions (compression, fluid/salt, postural optimization) are well-validated for orthostatic symptoms but have not been studied specifically for their effect on cognitive PEM frequency or cognitive metabolic reserve. Architecture C predicts that these interventions should reduce cognitive PEM in hEDS/POTS + ME/CFS patients by increasing cerebral blood flow during sustained cognitive effort. This is testable by measuring cognitive PEM frequency before and after implementing a comprehensive perfusion optimization protocol, with ASL-MRI cerebral blood flow as the mechanistic endpoint. Partially replicated for orthostatic symptoms; not yet tested for cognitive PEM specifically.
Certainty: 0.50 for individual components (standard POTS management); 0.30 for the metabolic reserve framing.
8 Osteopathic and Lymphatic Drainage: The Perrin Technique
The Perrin Technique, developed by British osteopath Dr. Raymond Perrin from 1989, combines lymphatic drainage effleurage with classical osteopathic spinal manipulation, targeting thoracic spine rigidity and lymphatic stagnation.
Theoretical basis: Thoracic spine rigidity impairs lymphatic drainage from the brain (the brain’s glymphatic/lymphatic system was only recently confirmed, though no study has directly demonstrated that Perrin’s technique affects glymphatic clearance). Stagnant lymphatic fluid allows toxin and metabolic waste accumulation in the central nervous system, potentially contributing to autonomic dysregulation. A sympathetic-dominant nervous system further slows lymphatic flow, creating a vicious cycle.
Diagnostic utility: Perrin et al. (2017, BMJ Open) identified five physical signs with 86% diagnostic accuracy in an experienced practitioner and 77% in a recently trained one (\(n = 52\) ME/CFS, 42 controls). The five signs include tender rigid thoracic spine, varicose lymphatics in the chest, a characteristic tender point above the left nipple (the Perrin point), tender solar plexus, and reduced cranio-sacral rhythm.
Efficacy evidence: Perrin et al. (2022) treated 20 Long~COVID patients with an average of 9 weekly sessions and measured improvement on a 54-item fatigue scale: 41.8% improvement in men, 60.5% improvement in women, with most scale items improving approximately 50%
Craniocervical considerations: Bragée et al. (2020) performed MRI on 229 ME/CFS patients and found craniocervical obstructions in approximately 80% This suggests structural spinal issues may be more prevalent in severe disease, though the direction of causality remains unclear.
No randomized controlled trial of the Perrin Technique exists for ME/CFS specifically. The Long~COVID study was uncontrolled (\(n = 20\)). The diagnostic study is promising but requires independent replication. Cost and treatment duration (weekly sessions for 3 months, then tapering over ~1 year) present accessibility barriers.
Combination hypothesis: See Synergistic CSF Volume Reduction and Neurolymphatic Drainage for a proposed synergistic combination with carbonic anhydrase inhibitors targeting glymphatic clearance failure from both sides (reduce CSF input + improve drainage output).